Boehringer Ingelheim Pharmaceuticals, Inc.

Farmaceutisch bedrijf10 producten gevolgd

producten gevolgd

271.920

totaal meldingen

recalls geregistreerd

61,6%

ernstig algeheel

Producten

10 van 10 getoond

Product	Goedgekeurd	Meldingen ↓	Top signaal	Recalls
tiotropium bromide —	2004	150.254	verkeerde toedieningsroute van medicijn	0
empagliflozin —	2014	69.331	Euglycemische diabetische ketoacidose	7
linagliptin —	2011	20.890	Blindheid	2
tiotropium bromide inhalation spray —	—	10.745	slaapstoornis door een algemene medische aandoening	0
afatinib —	2013	6.549	EGFR-genmutatie	0
tiotropium bromide and olodaterol —	—	4.837	COPD	0
empagliflozin, metformin hydrochloride —	—	3.303	Euglycemische diabetische ketoacidose	0
empagliflozin and metformin hydrochloride —	—	2.719	Euglycemische diabetische ketoacidose	4
empagliflozin and linagliptin —	—	1.913	Euglycemische diabetische ketoacidose	1
tipranavir —	2005	1.379	cloaca-extrofie	0

Recall-geschiedenis · 16 geregistreerd

Datum	Klasse	Reden	Bedrijf
9 mrt 2023	II	Labeling: Label Mix-up	Boehringer Ingelheim Pharmaceuticals, Inc.
26 jan 2022	II	CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.	CARDINAL HEALTHCARE
15 mrt 2021	II	CGMP Deviations: Intermittent exposure to temperature excursion during storage.	Cardinal Health Inc.
15 mrt 2021	II	CGMP Deviations: Intermittent exposure to temperature excursion during storage.	Cardinal Health Inc.
15 mrt 2021	II	CGMP Deviations: Intermittent exposure to temperature excursion during storage.	Cardinal Health Inc.
15 mrt 2021	II	CGMP Deviations: Intermittent exposure to temperature excursion during storage.	Cardinal Health Inc.
15 mrt 2021	II	CGMP Deviations: Intermittent exposure to temperature excursion during storage.	Cardinal Health Inc.
5 okt 2020	II	An extraneous peak was observed for dissolution testing.	Boehringer Ingelheim Pharmaceuticals, Inc.
5 okt 2020	II	An extraneous peak was observed for dissolution testing.	Boehringer Ingelheim Pharmaceuticals, Inc.
5 okt 2020	II	An extraneous peak was observed for dissolution testing.	Boehringer Ingelheim Pharmaceuticals, Inc.
7 mrt 2019	III	Failed Tablet/Capsule Specifications: identification of low weight tablets during routine stability testing.	Boehringer Ingelheim Pharmaceuticals, Inc.
22 okt 2018	II	Failed Dissolution Specifications: OOS resultsduring routine stability testing	Boehringer Ingelheim Pharmaceuticals, Inc.
4 sep 2018	II	Cross Contamination With Other Products:	Boehringer Ingelheim Pharmaceuticals, Inc.
22 sep 2017	III	Labeling: Incorrect or missing package insert. One lot of Mobic Tablets is packaged with an incorrect insert.	Boehringer Ingelheim Pharmaceuticals, Inc.
6 okt 2016	II	Presence of foreign tablets/capsules: 50 mg Persantine tablets were found in a 75 mg Persantine 100-count bottle and 50 mg Persantine tablet was found in a 100 count bottle of 75 mg Dipyridamole.	Boehringer Ingelheim Pharmaceuticals, Inc.
6 okt 2016	II	Presence of foreign tablets/capsules: 50 mg Persantine tablets were found in a 75 mg Persantine 100-count bottle and 50 mg Persantine tablet was found in a 100 count bottle of 75 mg Dipyridamole.	Boehringer Ingelheim Pharmaceuticals, Inc.

Class I = redelijke kans op ernstige schade · Class II = tijdelijk of omkeerbaar · Class III = onwaarschijnlijk schadelijk.

Registratiestatus

Sommige producten van Boehringer Ingelheim Pharmaceuticals, Inc. zijn niet FDA-geregistreerd voor humaan gebruik. Voor ongeregistreerde stoffen (peptiden, SARMs zonder humane registratie) bestaat geen legitieme leverancier voor humaan gebruik. Het ontbreken van een inkooproute is de veiligheidsinformatie.